Moleculent has announced the closing of a $20 million financing round that supports its mission to pioneer functional profiling. Namely, the capital will go toward expansion of Moleculent’s Techstart Early Access Program, supporting commercial launch of the company’s instrument. Moreover, the funding—Rubicon Healthcare Partners leading, with Arch Venture Partners, Eir Ventures, and others—accelerates United States commercial operations. Moleculent’s vision is to use functional profiling to ma...